Sfoglia per AUTORE
CAVO A
Collezione AO Ordine Mauriziano

  

Items : 13

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.

2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960.

2024
AO Ordine Mauriziano

Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE;

Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Jun;22(3):102074. doi: 10.1016/j.clgc.2024.102074. Epub 2024 Mar 18.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Cavo A; Bassanelli M; Formisano L; Mattana A; Marchetti A; Mennitto A; Di Napoli M; Pierantoni F; Grillone F; Vignani F; Calabrò F; Caffo O; Roviello G; Ermacora P; Iacovelli R; Vitale MG; Maiorano BA; Claps M; Bimbatti D; Maruzzo M; Massari F; Mollica V; Prati V; Giudice GC; Buti S;

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
AO Ordine Mauriziano

Messina C; Catalano M; Roviello G; Gandini A; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucal PA; Masini C; Naglieri E; Procopio G; Milella M; Catalano F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Soraru M; Prati V; Atzori F; Di Napoli M; Messina M; Morelli F; Prati G; Nole F; Malgeri A; Tudini M; et alii...

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. in Immunotherapy / Immunotherapy. 2024;16(18-19):1095-1103. doi: 10.1080/1750743X.2024.2385881. Epub 2024 Aug 19.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Murianni V; Catalano F; Nolè F; Prati G; Morelli F; Messina M; Atzori F; Tudini M; Prati V; Roviello G; Cavo A; Vignani F; Caffo O; Napoli MD; Malgeri A; Rebuzzi SE; Signori A; Cremante M; Damassi A; Rescigno P; Banna GL; Fornarini G; Buti S;

Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study. in Frontiers in immunology / Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Naglieri E; Malgeri A; Cavo A; Di Napoli M; Vignani F; Nolè F; Prati G; Morelli F; Atzori F; Caffo O; Prati V; Fratino L; Tudini M; Mollica V; Sorarù M; Ricotta R; Pipitone S; Zampiva I; Chiellino S; Claps M; Fornarini G; Zucali PA; Galli L; Buti S; De Giorgi U; Maruzzo M; Rebuzzi SE; Catalano M; Signori A; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12.

2024
AO Ordine Mauriziano

Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE;

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.

2023
AO Ordine Mauriziano

Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Procopio G; Chiellino S; Milella M; Catalano F; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; et alii...

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study. in Cancers / Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394.

2023
AO Ordine Mauriziano

Rebuzzi SE; Brunelli M; Galuppini F; Vellone VG; Signori A; Catalano F; Damassi A; Gaggero G; Rescigno P; Maruzzo M; Merler S; Vignani F; Cavo A; Basso U; Milella M; Panepinto O; Mencoboni M; Sbaraglia M; Dei Tos AP; Murianni V; Cremante M; Llaja Obispo MA; Maffezzoli M; Banna GL; Buti S; Fornarini G;

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Messina M; Caffo O; Di Napoli M; Atzori F; Santini D; Soto Parra HJ; Prati V; Cortellini A; Santoni M; Sorarù M; Mollica V; Panni S; Ricotta R; Pipitone S; Fratino L; Boccardo F; Milella M; Procopio G; Naglieri E; Fantinel E; Zucali PA; Galli L; Chiellino S; Basso U; De Giorgi U; Maruzzo M; Damassi A; Fornarini G; Gandini A; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Nolè F; Prati G; Morelli F; Messina M; Caffo O; Di Napoli M; Atzori F; Soto Parra HJ; Prati V; Cortellini A; Sorarù M; Santoni M; Massari F; Panni S; Ricotta R; Sabbatini R; Fratino L; Boccardo F; Milella M; Procopio G; Carella C; Fantinel E; Zucali PA; Galli L; Pedrazzoli P; De Giorgi U; Maruzzo M; Santini D; Stellato M; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano

Bersanelli M; Casadei C; Pierantoni F; Roviello G; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Messina C; Messina M; Pignata S; Atzori F; Stellato M; Soto Parra HJ; Prati V; Santoni M; Cortellini A; Sorarù M; Mollica V; Panni S; Ricotta R; Baldessari C; Fratino L; Tomasello L; Merler S; Procopio G; Naglieri E; Masini C; et alii...